AIM
BLPH

Acrospire Investment Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Acrospire Investment Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-113
Closed -$2K – 1826
2017
Q2 		$2K Buy
+113
New +$2.34K ﹤0.01% 2075

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acrospire Investment Management's BLPH Position: Q3 2017 in Review

Acrospire Investment Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q3 2017, closing a stake of 113 shares — an estimated $2K sold.

Acrospire Investment Management first reported a position in BLPH in Q2 2017 and held it in 1 quarter. The position peaked at $2K in Q2 2017. 17 funds tracked by Wall St. Rank hold BLPH as of Q3 2017.

  • Acrospire Investment Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 113 Bellerophon Therapeutics, Inc. shares in Q3 2017, an estimated $2K.
  • Acrospire Investment Management first reported a position in Bellerophon Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • Acrospire Investment Management's Bellerophon Therapeutics, Inc. position peaked at $2K in Q2 2017.
  • 17 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.